NION INTERDISCIPLINAIRE DE

ies. Touterept

### HERAPIE ANTI-INFECTIEUSE PALAIS DES CONGRES - PARIS PALA used with routine clinical samples at two hospitals in Paris Pr. Laurent DORTET Pr. Martin ROTTMAN 202700 © RICA 2021 TOUS droite where Hôpital Hôpital **Bicêtre** Raymond-Poincaré AP-HP AP-HP




- The Need for Rapid AST Escalation for south
  - Escalation for septic patients when prophylatelic treatment is not effective
    De-escalation to reduce cost, prevent development of resistance and safeguard the microbiome out to be optimal antibiotic reaction.
    Choose the optimal antibiotic reaction.
    pid ID alone is "usually" not out to be optimal down on the prophylater of the optimal down of the op


© RICAI 2021 TOUS droite eter **Rapid ID alone is "usually"** not sufficient to guide appropriate therapy change  $TO^{15}$   $C^{RLCP}$ 

# Principle of the Reveal instrument

- Printed volatile-responsive sensors reproduction Printed volatile-responsive sensors reproduction parts per billion) of smaller to sensors reproduction
  - Volatile emissions precede cell division, enabling a faster response than other division of volatiles in the headspace does not require the sample, simplifying council of the sample of Printed volatile-responsive sensors rapidly respond to low concentrations (10 parts per billion) of small volatile restabolites emitted during microorganism growth, on a well-by-well basis if a 96-well plate
  - cells from sample, simplifying sample preparation

## How is MIC determined Schoots responses to the volatile and which growth is a How is MIC determined









Study Plan Clinical validation study of the CE-IVD marked Reveal rapid AST System on **positive Blood cultures with** gram negatives

- Comparison of the Reveal results to Direct from Blood Disk Diffusion
- Discords (note, only major and very major errors were settled) between of reserved agreement
   Discords (note, only major and very major errors were settled) between of reserved agreement



# Results with the Reveal System in 2 Independent Labs

, e								
droitste	S	Pooled	Kremlip <sup>3</sup> Bicêtre <sup>n<sup>n</sup>e<sup>ne</sup>95.8% J<sup>c<sup>10</sup>3.5% (n=54) 0.5% (n=6) 1.6% (n=5) Eb 20min</sup></sup>	Raymond Poincaré				
	<b>Categorical agreement</b>	95.6%	an <sup>me</sup> 95.8%	95.4%				
	Minor Error ( $I \rightarrow R \text{ or } I \rightarrow S$ )	3.6%	ري <sup>زيري</sup> 3.5% (n=54)	3.7% (n=59)				
	Major Error (False R)	<b>0.8%</b>	0.5% (n=6)	1.0% (n=12)				
	Very Major Error (False S)	1.2% 5 <sup>e</sup>	1.6% (n=5)	0.8% (n=3)				
	Average Time to Result	5h 32 min	5h 29min	5h 35min	, s'e			
		eserve		5h 35min 7 To <sup>us</sup> 18 20 <sup>21</sup> 104 <sup>20</sup>	droit			
	Species	oitsie	8	7 100	2			
	Antibiotics	, die	17	18 202				
	Strains	204	100	1Q4 <sup>P</sup>				
	$R(\%) = (\%)^{2^{0}r}$	21.65%	19.79%	2\$.50%				
	Very Major Error (False S) Average Time to Result Species Antibiotics Strains R (%) ORICH 2017							



### Performance by antimicrobial

Antimicrobial agent	Total	TTR	mE	ME	VME	CA	Antimicrobial agent	Total	TTR	mE	ME	VN	ΛE
Amikacin	100	4h 37m in	<sup>x</sup> 4	0	0	96.0%	Amikacin	104	4h 50min	5	0	0	
Ampicillin	46	3h 39min	0	0	0	100.0%	Amikacin Aztreonam Cefepime Cefotaximes <sup>tieleestin</sup> Cefotaximes <sup>tiele</sup>	86	5h 40min	5	0	0	
Aztreonam	95	5th 36min	5	1	0	93.7%	Cefepime	102	6h 01min	4	1	0	
Cefepime	100	<sup>56</sup> 6h 05min	4	1	1	94.1%	Cefotaximes <sup>xie</sup>	79	5h 42min	2	1	0	
Cefotaxime	90 <sup>°</sup>	5h 56min	4	0	0	95.6%		64	5h 12min	0	0	0	
Cefoxitin	69	4h 43min	0	1	0	98.6%	Ceftazidime	102	6h 05min	2	0	0	
Ceftazidime	97	5h 58min	7	0	0	92.9%	Ceftolozane/Tazobactam	25	6h 31min	0	0	0	
Ceftazidime/Avibactam	98	6h 19min	0	0	1	99.0%	o <sup>xe</sup> Cefuroxime	60	4h, æðmin	0	0	0	
Ciprofloxacin	100	5h 05min	3	2	0	94.18	Ciprofloxacin	104 760 <sup>55</sup>	Sh 22min	5	7	0	
Ertapenem	89	6h 31min	4	0	0	95.5%	Ertapenem	760 <sup>55</sup>	6h 31min	0	0	0	
Gentamicin	100	5h 59min	0	0	0,0	هُ`100.0%	Gentamicin	103	6h 00min	0	1	0	
Imipenem	99	6h 31min	1	0	<sup>29</sup> 0	99.0%	Imipenem 🔊 🌾	<sup>C</sup> 103	6h 31min	1	0	1	
Levofloxacin	99	5h 12min	4	O	1	95.0%	Levofloxacin	104	5h 21min	5	0	0	
Piperacillin	100	4h 15min	2	1	0	96.0%	Meropenem	103	6h 31min	10	0	0	
Piperacillin/Tazobactam	93	6h 35min	11	0	2	85.1%	Piperacillin	103	4h 24min	2	2	0	
Tobramycin	99	4h 38min	5	0	0	95.0%	Piperacillin/Tazobactam	<b>102</b>	6h 32min	15	0	1	
Trimethoprim/Sulfa	87	4h 38min	0	0	0	98.9%	Tobramycin	104	4h 46min	1	0	0	
	1561		54	6	5	95.8%	Trimethoprim/Sulfa	79	4h 17min	2	0	1	
								1604		59	12	3	

# Several discords with direct disk diffusion were resolved in favor of Reveal Joursteen Nere particle of the swith VMEs after discord adjudication Nere particle of the swith VMEs after discord adjudication Nere particle of the swith 12 5 reveal 10 6 Raymond 19 25 reveal 18 12 Of the initial VMEs, 15 were against Piperacillin/tazobactam, and discord particle of the swith protocollution resolved 10 of these in favor of Reveal particle of the swith protocollution may be problematic for Pip-Tazo. indicating direct disp diffusion may be problematic for Pip-Tazo.

# Conclusions environmenter envi

## Reveal performs in accordance with GE-IVD claims

- Performance 95.5% accuracy with just 1% VME, at two hospitals in • Paris, performed by different teams, different local epidemiologies
- Time to result approximately 5.5 bours, averaged over all drugs and strains
   Plausible, same-shift guidance for bacteremia therapy (in
- © RICA 2021 TOUS draite ater ICU ? or severe patients ?)
   Easy to handle ?<sup>90</sup> quick workflow

- Perspectives environmenters environm
- Interesting results that to have to be confirmed for gram positives
   Bacterial panel have to be enlarge to other species (e.g. S. marcescens, M. morganiich Enterobacterales)
   Iedico-economical states
  - Medico-economiosimpact vs Rapid ID +  $\beta$ -LACTA® test on Tous de la constant de



ARDI 14 RE 2021 AIS DES CONGRES - PARIS DES CONGRES - PARIS AIS DES CONGRES - PARIS CENCONGRES - PARIS DES CONGRES - PARIS CONGRES - PARIS DES CON

